Innovaderma Share Discussion Threads

[conversev2] 21/2/2019 13:58

spent the morning talking to the broker.
the key thing to focus on is the story going forward.....
Anyone can re-hash negative stories from the past twelve months, but the key to making money in a difficult market is spotting a turnaround stock. We believe that IDP fits that profile.
Obviously after reading all the posts its obvious people are putting there own slant on the news (dependant if you're a bull or bear), but maybe we should just focus on a couple of key facts:

1) This was a complete basket case that got puffed up in a good market.
2) The product is now sound and is selling well
3) The correct management are now in place to drive the company forward.
4) The balance sheet is in good shape, and no new equity should need to be raised.

As everyone is aware, after this positive update (im talking about the forward statement - not the past disappointments), IDP still have a further two RNS' to release; The long awaiting Boots order and FDA clearance.
Obviously, this is a high risk play, but sub 100p we see plenty of upside in the next twelve months.

[fardistanthills] 21/2/2019 13:45

kemche, one of the very very very few on here who tell it like it is.

[kemche] 21/2/2019 13:36

Yes muz, but that is only a 29% increase in revenues, 114% increase in PBT, and a paltry increase of 218% in EPS. At 88p they are already trading at a very very very very scary 12 times.

They will also require invoice discounting or other banking facilities which is very very very very bad.

I can see the price here going well below zero which will be very very very very bad.

It is all very very very very very scary and stuff.

etc.


That's my analysis and I am sticking by it!

[muzmanoz] 21/2/2019 13:19

Finncap still forecasting good growth in its numbers at:

revenue £13.2m (2018 £10.2m)
PBT £1.5m (2018 £0.7m)
eps 7.0p (2018 2.2p)

[gregpeck7] 21/2/2019 13:07

Yep they need banking facilities as the equity game is up here..

[sphere25] 21/2/2019 11:43

FinnCap cut revenues, PBT and EPS by 8%, 10% and 6% respectively. However, Chowdry telling the market that performance will be in line.....oooerrr gavnar!!

You need to watch out for folk like Chaudhry. This guy was dumping in size whilst sending out bullish statements to the market - look at how the stock has crashed since. All hype and no delivery so far.

This is a very very high risk play. You should be prepared to lose the majority of your holding with Chaudhry at the helm. He'll be ok though, he has banked some very tidy sums!

Plenty of snakes in the grass out there.

Sphere - no position

All imo

[hatfullofsky] 21/2/2019 10:31

Let's hope history does not repeat itself ....

08/03/18

The Company has made considerable progress and the Board continues to expect the second half year to outperform the first half significantly, however revenue growth for the year will now be less than anticipated at the time of the interim results. This has been mainly driven by lower than expected orders placed by Superdrug for Skinny Tan despite the brand's continued growth.

Superdrug was the first stockist so hopefully Boots have more sales data to make decisions on.

Positive start but we need the FY update to confirm (normally in June)

[kemche] 21/2/2019 09:32

The filter button comes into play again.

[haroldthegreat] 21/2/2019 09:17

Luckily as most people would not discuss this problem the loss would just be limited to that customer.
They could go back to a local anaesthetic gel or spray to solve the problem.

[haroldthegreat] 21/2/2019 09:12

New definition of frustration. You suffer from premature ejaculation so you spend $300 on a device to solve then problem. You then find you cannot turn it on .or you turn it on and cannot turn it off and the battery goes flat .thats what happens when you go for the cheapest quote !

[muzmanoz] 21/2/2019 08:45

Finncap adjusted it's target price to 200p (from 220p) following adjustments to revenue, pbt and eps.Basically reiterates that h2 is dependent on boots order and reorder levels but remains positive.

[tallprawn] 21/2/2019 08:43

90.20 to buy - MM's Looking for stock right now.

[hatfullofsky] 21/2/2019 08:40

Results as expected, outlook good, excellent start to period with recovery in DTC +34%.

Cash at 700k v £1.9M so quite an investment made FY but not at risk and I like the Banking Facilities discussion, expect news soon which will underpin the share price

[tallprawn] 21/2/2019 08:35

That's old news though - It's since been fixed and a newly designed switch is on the product now. Marketing has restarted and sales will be building.Whilst annoying at the time, the company has now dealt with it. The real point to look at with Prolong is the imminent introduction into Europe, India and China - Big markets to drive sales in.

[molatovkid] 21/2/2019 08:32

£12m cap gives this multi-bag potential too.....

[haroldthegreat] 21/2/2019 08:32

Must add to frustration.......you have a problem and buy an expensive "cure " you then find a problem with the switch doesnt say much for quality control.

Prolong, the world's only FDA-cleared medical device for premature ejaculation, was launched in the United States and Australia in May 2018. The launch was supported by a highly creative marketing campaign however the campaign was halted in July 18 owing to a switch defect in the initial manufactured inventory. This has now been
resolved with a new manufacturer onboard and the Company has recommenced the marketing campaign.

[zico01] 21/2/2019 08:24

2nd half going great guns so far total sales well ahead of last year i'm well impressed.

[tallprawn] 21/2/2019 08:24

Should have a long open if he has any sense now! We're heading north and fast.

[molatovkid] 21/2/2019 08:22

Looks like dear john has scurried off to close that short.....

[coldspring] 21/2/2019 08:19

Moves big on very little volume. Standby for action.

[tallprawn] 21/2/2019 08:18

Here comes the bounce - Bye bye 80p's and 90p's very soon.

[nobbygnome] 21/2/2019 08:17

Bought a few this morning. All that really matter is the current trading statement....

[foolishben] 21/2/2019 08:16

Very happy with the outlook statement. Last year H2 revenue was £6.5m. In the first six weeks of current H2 group revenue is up 37%. Even if they just maintained that level the H2 revenue would be £8.9m which would make for full year revenue of £12.8, a 20% rise on last year. Of course with the Boots rollout taking place in mid-march we will have 3.5 months of sales from an additional 1305 stores so it very much looks like the original £14m revenue forecast will be hit and I'd suggest there is more upside risk than down to that. Without wishing to sound too rampy, I think think the market have been very slow to catch up with what is going to happen at this company over the next couple of years. I already held and just took advantage of the mark down to buy another 10k shares.

[kemche] 21/2/2019 08:15

hxxps://growlase.com

Well that was fast!

$399 a pop.

I am led to believe that the margin on this is quite eye watering.

I hope IDP are not going to ruin their reputation by actually starting to deliver on their promises!

:)

[tallprawn] 21/2/2019 08:12

It's on Research Tree - You can sign up for a free login to view it. https://www.research-tree.com/companies/uk/personal-goods/innovaderma